Resumen de: WO2023097102A2

The present disclosure relates to a vaccines and related polynucleotides useful in eliciting an immune response to the SARS-CoV-2 virus and related methods of use.

Resumen de: WO2023094383A1

A bipolar composite material comprising:(i) a clay whose precursor is an asymmetric 1:1 or 2:1:1 clay particle, comprising alternating tetrahedral and octahedral sheets terminating with a tetrahedral sheet at one external surface plane and an octahedral sheet at another; and,(ii) antimicrobial quaternary ammonium compound attached to a coordinating cation on one of said external surface planes, in a composition for use in the reduction of transmission of SARS-CoV-2 (covid 19).

Resumen de: WO2023096265A1

The present invention relates to a device and method for deriving a severity prediction score of a COVID-19 patient using a biological signal. The method for deriving a severity prediction score of a COVID-19 patient using the device for deriving a severity prediction score according to the present invention comprises the steps of: collecting personal information and a biological signal, sensed by a wearable biological signal device, of a mild COVID-19 patient; calculating a COVID-19 severity score of the patient using the personal information and biological signal of the patient; and predicting the patient's severity of COVID-19 by using the COVID-19 severity score of the patient. The personal information of the patient includes age and gender of the patient and whether or not the COVID-19 is a recurring case. The biological signal includes at least one from among a pulse rate, oxygen saturation, systolic blood pressure, diastolic blood pressure, body temperature, and whether or not the patient has hypertension.

Resumen de: WO2023095990A1

The present invention relates to a lighting device using a PCB on which a sterilization LED emitting light in the visible spectrum and an LED having an infrared wavelength are connected, wherein the lighting device is harmless to the human body due to minimizing blue light wavelengths while emitting colored light, and has a sterilization effect. To this end, the present invention comprises a PCB on which an infrared LED package and a UV LED package including a first UV LED package and a second UV LED package are arranged, wherein the first UV LED package emits colored light and includes one or more first LED chips, which emit light having a center wavelength of 405 nm, and a phosphor layer formed on the first LED chips. Using the lighting device according to the present invention reduces damage from blue light while lighting a room with colored light, and is also effective for killing the COVID-19 virus due to the sterilization effect. By replacing lighting installed in public transportation and multi-use facilities with the lighting device according to the present invention, it is possible to naturally reduce the spread of the COVID-19 virus and provide a sterilization effect while providing illumination.

Resumen de: WO2023095860A1

The present invention provides a medicine useful for treating and/or preventing COVID-19. Provided is a medicine characterized by combining: (A) a compound represented by formula (I) (where: Y is N; R1 represents an optionally substituted aromatic heterocyclic group; R2 represents an optionally substituted 6-membered aromatic carbon ring group; R3 represents an optionally substituted aromatic heterocyclic group; -X- is -NH-; m is 0 or 1; R5a represents a hydrogen atom; R5b represents a hydrogen atom; n is 1; R4a represents a hydrogen atom; and R4b represents a hydrogen atom) or a pharmaceutically acceptable salt thereof; and (B) a COVID-19 aggravation inhibitor.

Resumen de: WO2023095018A1

The present invention relates to a rapid method to perform reverse transcription loop-mediated isothermal amplification (RT-LAMP) and LAMP at room temperature between 25-42°C, more specifically at 25-37°C, to detect RNA/DNA in a sample and a reagent kit thereof. Further, the invention relates to an in vitro method to detect SARS-CoV2 using RT-LAMP at room temperature between 25-42°C, more specifically at 37°C. The reagent kit comprises of enzymes/proteins - Klenowexo-/-, ApaI, High fidelity Taq Pol, Rpa32, StpA, AMV-RT for reverse transcriptase; buffer composition of - Tris-HCl, MgSO4, KCl, DTT, PEG, DMSO, 1mM dNTPs each, at least 4 primers, and fluorescent dye, more specifically propidium iodide.

Resumen de: WO2023092180A1

The present invention relates to the treatment or prevention of SARS-CoV-2 infection or COVID-19. In particular, the present invention relates to the use of N-carbamimidoyl-5-(1-methyl-1H-pyrazol-4-yl)-2-naphthamide, or a pharmaceutically acceptable salt thereof, in the treatment or prevention of SARS-CoV-2 infection or COVID-19.

Resumen de: AU2021344872A1

A method for facilitating epidemiologic surveillance for a target disease such as Covid-19 includes a step of using an optical identifier such as a barcode or a numerical code to rapidly report de-identified test results to a central database. A rapid test device may be based on a direct flow point-of-care device comprising a porous membrane with at least one recombinant antigen applied thereto and procedural control. The recombinant antigen may comprise an epitope for detecting the target disease marker. The first optical identifier may be applied to the device and facilitate remote communication of the test results without the use of any specialized equipment. The method and kit may also be used for generating data useful for a Covid-19 Passport.

Resumen de: US2023166066A1

According to the CDC, the same month (March, 2020) they declared COVD-19 a pandemic, nearly 25% of confirmed COVID-19 hospitalized patients required intubation, or ventilator use. More recently, in the US, during the summer of 2021, child intubations more than quadrupled, when the Delta variant predominated.As Omicron and additional COVID-19 variants continue to arise globally, there will be an increasing number of sudden spikes in critical illness and respiratory failure. Preparedness with efficacious airway tools that optimize success rate of intubations is critical.Without the proper tools, intubation procedures take excessive time, and can fail entirely, causing diminished central nervous system oxygenation and potentially permanent neurologic sequelae. Airway adjuncts such as the Tracheal Introducer Sheath (TIS) and Simplified Tracheal Introducer Sheath (STIS) hold immense potential to improve chances of successful intubations.The TIS is a STIS with an added articulating mechanism, but otherwise is a similar device. For the purposes of further explanation, the TIS refers to both TIS and STIS unless otherwise specified.TIS is an adjunct medical device for control and guidance of any form of tracheal introducer device through the glottic opening of a patient's airway. This facilitates endotracheal intubation by passage of the endotracheal tube.An airway introducer is placed within and controlled by the TIS, a mechanically specialized sheath, open at both ends, and covering

Resumen de: WO2023094967A1

Described herein are oral vaccine compositions for preventing and treating COVID and COVID related complications (e.g., cytokine storm related complications). These oral vaccine compositions comprise hydrolyzed and heat inactivated anti-viral antisense and other nucleic acid components that target the expression of SARS-CoV-2 viral proteins. Such oral vaccine compositions are room temperature stable and stimulate humoral (antibody), cellular and mucosal immunity.

Resumen de: US2023165912A1

A probiotic composition comprising Bifidobacterium bifidum and Bifidobacterium longum, and may further comprising Bifidobacterium adolescentis and Lactobacillus rhamnosus is provided. A prebiotic composition comprising xylooligosaccharide, galactooligosaccharide, and corn dietary fiber, and a dietary composition comprising the probiotic composition and the prebiotic composition are provided. Use of the foregoing compositions in the preparation of a dietary product or a drug for assisting in preventing and/or treating a pathogen infection of an individual, enhancing the therapeutic effect of a pathogen infection of an individual, improving the immunity of an individual, or balancing the gut microecology of an individual is provided. The foregoing compositions can be used in patients suffering from COVID-19.

Resumen de: US2023165914A1

Methods are provided for treating COVID-19 patients to facilitate their recovery from the disease as well as for prognosis of severity of COVID-19 among patients who have been infected by SARS-CoV-2. Also provided are kits and compositions for use in these methods.

Resumen de: US2023165943A1

Certain embodiments are directed to using TP508 as a drug that can restore prevent alveolar damage, reducing pulmonary edema and prevent respiratory failure and mortality-associated progression of COVID-19.

Resumen de: US2023165936A1

Broad spectrum antiviral peptides and composition including therapeutically effective amounts of the antiviral peptides along with a pharmaceutically acceptable carrier are provided. The antiviral compositions show a strong broad spectrum antiviral effect, without resulting to viral resistance. The antiviral compositions are useful for treatment of diseases caused by viral infections, particularly respiratory viruses such as enveloped coronaviruses (SARS-CoV-2, SARS-CoV and MERS-CoV), the pandemic A(H1N1)pdm09 virus, avian influenza A(H7N9) virus, and the non-enveloped rhinovirus.

Resumen de: US2023165951A1

This document relates to materials and methods for engineering and production of highly soluble, functional active recombinant Nucleocapsid (N) and Spike (S) based vaccine candidates against highly pandemic SARC-CoV-2 infection, in Nicotiana benthamiana plant using a transient expression system.

Resumen de: US2023165918A1

Disclosed are treatments, compositions of matter, and protocols for reducing, ameliorating, or reversing excess inflammation and/or cytokine storm through administration of Sphagnum and/or extracts thereof. In particular embodiments, a patient at risk for cytokine storm is administered a Sphagnum extract at a concentration sufficient to induce an immunomodulatory change in said patient, including suppression of macrophage activation, reduction of neutrophil activation and inhibition of DNA extracellular trap release. In some embodiments, Sphagnum, or extracts thereof are administered together with other agents to enhance activity in treatment of Covid-19 infection and associated pathologies. In some embodiments, humic acid and/or analogues thereof are administered for reduction of pathological inflammation and/or stimulation of immunity.

Resumen de: US2023165924A1

The present invention relates to a herbal formulation for the prevention and management of COVID-19 comprising hydro-alcoholic and n-hexane extracts of Hippophae rhamnoides, and hydro-alcoholic extracts of Tinospora cordifolia and Occimum sanctum and the bio-molecules of the said plants regulate the ACE2 receptors in different organ system.

Resumen de: US2023165890A1

According to the invention, to treat severe progression of viral infections, in particular SARS-CoV-2 infections, heparin or one of its derivatives and/or another pharmaceutically acceptable polyanion is used in therapeutic apheresis, wherein a patient's blood is treated in an extracorporeal circuit such that a) blood cells are separated from plasma, b) a suitable amount of heparin/heparin derivative or pharmaceutically acceptable polyanion is added to the plasma, c) the pH of the plasma is decreased to <6 by means of a suitable buffer, d) precipitated substances are separated out, e) excess heparin and/or polyanion is adsorbed on an adsorber, f) the pH is increased back to the physiological value, and g) the treated plasma together, in parallel or successively with blood cells and, where necessary, a saline solution is reinfused into the patient.

Resumen de: US2023165881A1

Aspects of the disclosure relate to oligosaccharide compositions and methods of making the same. Also provided are methods of using oligosaccharide compositions as microbiome metabolic therapies for treating respiratory viral illnesses, such as COVID-19.

Resumen de: US2023165856A1

The present disclosure is directed to the use of dapagliflozin and ambrisentan for the treatment and prevention of coronavirus disease 2019 (COVID-19), SARS-CoV-2 infection, and/or symptoms thereof.

Resumen de: US2023165876A1

T he present invention provides methods of treating COV-ID-19 in a subject using methylthioninium compounds.

Resumen de: US2023165875A1

The present invention provides methods of treating COVID-19 in a subject using methylthioninium compounds.

Resumen de: US2023165826A1

The present invention is directed to compositions for administration of camostat mesylate or nafamostat mesylate to subjects by inhalational delivery, and to methods of treatment of COVID19 by administering such compositions to subjects by inhalational delivery.

Resumen de: US2023165834A1

Solubilized Alpha Lipoic Acid, solubilized Epigallocatechin 3-gallate, and solubilized Curcumin in combination as therapeutic agent(s) for the prophylaxis and/or treatment of arthritis including, without limitation, fibrotic disease, inflammatory disease, neurodegenerative disease, autoimmune disease, or heart and vascular disease as a consequence of arthritic pathophysiology, and viral infections including SARS-CoV-2 infections. There is also described the use of the solubilized therapeutic agent(s) for oral administration, and for inhalative administration.

Resumen de: US2023165524A1

Systems, devices, and methods are provided to facilitate the implementation of a “proning protocol” to improve a clinical outcome for a person having SARS-CoV-2 (COVID-19) or other condition that may benefit from spending time in the prone position. For example, a system may include a mobile device (e.g., smartphone, tablet, etc.) providing a proning application configured to manage a configuration and implementation of a proning protocol for a person and configured to receive sensor data from (a) a wearable sensor device secured to the person and including sensor(s) (e.g., accelerometer(s)) that monitor the person body position, and/or (b) other sensor(s) that monitor other physiological parameters relative to the proning protocol. The proning application may determine and output feedback to manage the person's position based at least on the received sensor data and defined parameters of the proning protocol.